Even though downregulation of the MYC oncogene can strongly reduce the growth of KRAS mutant NSCLC, we observed that only a distinct subgroup of NSCLC was affected in this way by JQ1 treatment. This evidence concerns the gene MYC and non-small cell lung carcinoma.